Skip to the main content.

Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Published Health Economics Study Shows a High Disease Burden Associated with Stress/Mixed Urinary Incontinence to U.S. Payers

Veranex’s Commercial Strategy and Market Access team members, Manasi Datar, PhD, Li-Chen Pan, MPH, and Thomas F. Goss, PharmD, along with members from Renovia, Inc. successfully published a peer-reviewed manuscript in Neurology and Urodynamics highlighting the significantly high healthcare resource utilization and costs in female patients diagnosed with stress or mixed urinary incontinence (SUI/MUI). This evidence suggests that more effective treatments are needed for women suffering from this condition and urges payers to increase access to innovative treatments in this population.

Veranex Supports Retrospective Claims Analysis of Physical Therapy Utilization Among Women With Stress or Mixed Urinary Incontinence

Manasi Datar, Li-Chen Pan, and Thomas Goss, members of the Veranex Commercial Strategy and Market Access team, supported the retrospective...

Read More

3 min read

Case Study: Optimizing Pricing Strategies for a Medical Device Product Family

Background A leading global medical device manufacturer faced a pricing strategy challenge and partnered with Veranex (formerly Boston...

Read More

Dasiglucagon Demonstrates Reduced Costs in the Treatment of Severe Hypoglycemia in a Budget Impact Model

Jordan Hinahara and Thomas Goss, members of our Commercial Strategy and Market Access team, contributed to the budget impact model. The...

Read More